www.psychiatriepropraxi.cz / Převzato z: Neurol. praxi. 2023;24(2):132-139 / PSYCHIATRIE PRO PRAXI 95 MEZIOBOROVÉ PŘEHLEDY Genetické faktory ovlivňující věk nástupu Huntingtonovy nemoci a markery jeho predikce které nám možná odhalí nové způsoby, jakými může být rozvoj a průběh choroby modifikován. Autor by rád vyjádřil poděkování prof. MUDr. Evě Kubala Havrdové, CSc., jejíž erudice a přístup jej motivovaly ke studiu neurověd se zaměřením na neurodegenerativní onemocnění. LITERATURA 1. Achenbach J, Saft C. Another Perspective on Huntington’s Disease: Disease Burden in Family Members and Pre ‑Manifest HD When Compared to Genotype‑Negative Participants from ENROLL‑HD. Brain Sciences. 2021;11(12):1621. doi:10.3390/brainsci11121621. 2. Aylward E, Mills J, Liu D, et al. Association between Age and Striatal Volume Stratified by CAG Repeat Length in Prodromal Huntington Disease. PLoS Currents. Published online 2011. doi:10.1371/4f7c7cf783354. 3. Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. Journal of Neurology, Neurosurgery & Psychiatry. 2010;82(4):405-410. doi:10.1136/jnnp.2010.208264. 4. Aziz NA, van Belzen MJ, Coops ID, Belfroid RDM, Roos RAC. Parent‑of‑origin differences of mutant HTT CAG repeat instability in Huntington’s disease. European Jour‑ nal of Medical Genetics. 2011;54(4):e413-e418. doi:10.1016/j. ejmg.2011. 04. 002. 5. Bakels HS, Roos RAC, Roon-Mom WMC, Bot ST. Juvenile- -Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review. Movement Disorders. 2021;37(1):16-24. doi:10.1002/mds.28823. 6. Chaganti SS, McCusker EA, Loy CT. What do we know about Late Onset Huntington’s Disease? Journal of Hun‑ tington’s Disease. 2017;6(2):95-103. doi:10.3233/jhd-170247. 7. Henley SMD, Wild EJ, Hobbs NZ, et al. Whole‑brain atrophy as a measure of progression in premanifest and early Huntington’s disease. Movement Disorders. 2009;24(6):932936. doi:10.1002/mds.22485. 8. James CM, Houlihan GD, Snell RG, Cheadle JP, Harper PS. Late‑onset Huntington’s Disease: A Clinical and Molecular Study. Age and Ageing. 1994;23(6):445-448. doi:10.1093/ ageing/23. 6. 445. 9. Killoran A, Biglan KM, Jankovic J, et al. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology. 2013;80(22):2022-2027. doi:10.1212/wnl.0b013e318294b304. 10. Kwa L, Larson, D, Yeh, C, Bega D. Influence of Age of Onset on Huntington’s Disease Phenotype. Tremor and Other Hyperkinetic Movements. 2020;10(0):21. 11. Labuschagne I, Jones R, Callaghan J, et al. Emotional face recognition deficits and medication effects in pre‑manifest through stage‑II Huntington’s disease. Psychiatry Research. 2013;207(1-2):118-126. doi:10.1016/j.psychres.2012. 09. 022. 12. Lahue Robert S. New developments in Huntington’s disease and other triplet repeat diseases: DNA repair turns to the dark side. Neuronal Signaling. 2020;4(4). doi:10.1042/ ns20200010. 13. Langbehn D, Brinkman R, Falush D, et al. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clinical Genetics. 2004;65(4):267-277. doi:10.1111/j.1399-0004.2004.00241.x. 14. Langbehn DR, Hayden MR, Paulsen JS. CAG‑repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. Ame‑ rican Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2009;153 B(2):397-408. doi:10.1002/ajmg.b.30992. 15. Lee JM, Correia K, Loupe J, et al. CAG Repeat Not Polyglutamine Length Determines Timing of Huntington’s Disease Onset. Cell. 2019;178(4):887-900.e14. doi:10.1016/j. cell.2019. 06. 036. 16. Lee JM, Wheeler Vanessa C, Chao Michael J, et al. Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease. Cell. 2015;162(3):516-526. doi:10.1016/j.cell.2015. 07. 003. 17. Li L, Liu H, Dong P, et al. Real‑time imaging of Huntingtin aggregates diverting target search and gene transcription. eLife. 2016;5. doi:10.7554/elife.17056. 18. Martínez‑Horta S, Horta‑Barba A, Perez‑Perez J, et al. Impaired face‑like object recognition in premanifest Huntington’s disease. Cortex. 2020;123:162-172. doi:10.1016/j. cortex.2019. 10. 015. 19. Reiner A, Dragatsis I, Dietrich P. Genetics and Neuropathology of Huntington’s Disease. International Review of Neurobiology. 2011;98:325-372. doi:10.1016/b978-0-12381328-2.00014-6. 20. Roth J. Huntingtonova nemoc. Cesk Slov Neurol N. 2010;73/106(2):107-123. 21. Scahill R, Zeun P, Osborne‑Crowley K, et al. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease Young Adult Study (HD‑YAS): a cross‑sectional analysis. The Lancet Neurolo‑ gy. 2020;19(6):502-512. 22. Schultz JL, Moser AD, Nopoulos PC. The Association between CAG Repeat Length and Age of Onset of Juvenile‑Onset Huntington’s Disease. Brain Sciences. 2020;10(9):575. doi:10.3390/brainsci10090575. 23. Semaka A, Collins JA, Hayden MR. Unstable familial transmissions of Huntington disease alleles with 27-35 CAG repeats (intermediate alleles). American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2009;9999 B:n/a ‑n/a. doi:10.1002/ajmg.b.30970. 24. Semaka A, Kay C, Doty C, et al. CAG size‑specific risk estimates for intermediate allele repeat instability in Huntington disease. Journal of Medical Genetics. 2013;50(10):696703. doi:10.1136/jmedgenet-2013-101796. 25. Stuitje G, van Belzen MJ, Gardiner SL, et al. Age of onset in Huntington’s disease is influenced by CAG repeat variations in other polyglutamine disease‑associated genes. Brain. 2017;140(7):e42-e42. doi:10.1093/brain/awx122. 26. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK‑HD study: cross‑sectional analysis of baseline data. The Lancet Neurology. 2009;8(9):791-801. doi:10.1016/s1474-4422(09)70170-x. 27. Tezenas du Montcel S, Durr A, Bauer P, et al. Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes. Brain. 2014;137(9):2444-2455. doi:10.1093/ brain/awu174. 28. Todd TW, Lim J. Aggregation formation in the polyglutamine diseases: Protection at a cost? Molecules and Cells. 2013;36(3):185-194. doi:10.1007/s10059-013-0167-x. 29. Wheeler VC, Persichetti F, McNeil SM, et al. Factors associated with HD CAG repeat instability in Huntington disease. Journal of Medical Genetics. 2007;44(11):695-701. doi:10.1136/ jmg.2007.050930. 30. Wijeratne PA, Garbarino S, Gregory S, et al. Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease. Neurology Genetics. 2021;7(5):e617. doi:10.1212/nxg.0000000000000617. Fakultní nemocnice Královské Vinohrady oznamuje volnou pracovní pozici pro Požadujeme: VŠ vzdělání lékařského směru specializovanou způsobilost v oboru psychiatrie dle zákona č. 95/2004 Sb. ambulantní a konziliární činnost celý nebo částečný úvazek (min. 0,4) LÉKAŘE – PSYCHIATRA Přihlášky se strukturovaným životopisem zasílejte na adresu: Fakultní nemocnice Královské Vinohrady Bc. Zdeněk Pastyřík, MBA Personální náměstek Šrobárova 50, 100 34 Praha 10 e-mail: pastyrik@fnkv.cz.
RkJQdWJsaXNoZXIy NDA4Mjc=